Psychedelic therapists, pharma collaborate on clinical trial

Summary

A groundbreaking initiative in Psychedelics and Drug Studies is advancing medicine. A New York organization, a global leader in professional medical education for psychedelic therapy, is collaborating with a biotechnology company. They are developing an FDA-approved botanical psilocybin medicine for an upcoming randomized controlled trial. This effort aims to establish psilocybin's role as an alternative medicine, potentially revolutionizing psychology. The future clinical trial will provide vital insights into this promising field of medicine.

Abstract

A New York‐based organization, considered a global leader in professional education and training for psychedelic therapy research, is collaborating with a biotechnology company to develop an FDA‐approved botanical psilocybin pharmaceutical candidate to support an upcoming randomized clinical trial.

Tags